Becton, Dickinson and Company (BDX:NYSE) closed at $198.91 on October 23, 2026, down 0.75% on the day. The stock trades 0.8% below its 52-week high of $200.47 and 55.9% above its 52-week low of $127.59. Over the past year, it gained 36.2%. Becton, Dickinson and Company is part of the Health Care sector (Medical/Dental Instruments).
In 252 trading sessions since October 23, 2025, BDX closed higher on 115 days (46%). Its best day was May 7, 2026 (+5.87%) and its worst was May 11, 2026 (-4.20%). It never moved 10% or more in a single session.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and IV sets for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laproscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation, and plated media products; fluorescence-activat...
Find more stocks like BDX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.